Free Light Chains (FLCs) are immunoglobulin light chains which are circulating in serum in a free state (unbound). There are two types of immunoglobulin light chain produced in humans, designated kappa (κ) and lambda (λ).
The quantification of serum FLC is used as an aid in the diagnosis and monitoring patients with Multiple Myeloma.
Ratio FLC value (kappa FLC/lambda FLC) compared to reference ranges may indicate presence of plasma cell disorders disease like Multiple Myeloma or AL amyloidosis in a patient.
Nephelometric and turbidimetric based assays have been shown to overestimate the sFLC levels that are not always consistent with Serum Protein Electrophoresis/Immunofixation and other clinical parameters.
Reliable and high analytical performance results
with correct estimation of FLC values without antigen excess or overestimation by polymerization vs Nephelometry / Turbidimetry Methods.
Trust in the results
with concordance value between SPE and FLC Kappa & FLC Lambda which help on interpretation results.
Easy to implement
for patient therapy monitoring and meeting IMWG guidelines.
4 times lower retest rates
vs other methods and lower manual dilutions needed.
Easily adapted and scalable
to any type of ELISA Instrument for standardization and efficiency process.
Quantification of Kappa or Lambda Free Light Chains is performed with an Enzyme-Linked Immunosorbent Assay (ELISA) procedure utilizing specific antibodies anti-Kappa or anti-Lambda free light chains.
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.